BIPAR SCIENCES
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors. BiPar has raised around $60 million in VC funding, from firms like [Domain Associates](/financial-organization/domain-associates), [Canaan Partners](/financial-organization/canaan-partners-3), [Vulcan Capital](/financial-organization/vulcan-capital), [PolyTechnos Ven... ture Partners](/financial-organization/polytechnos-venture-partners), [Asset Management Company](/financial-organization/asset-management), and [Quantum Technology Partners](/financial-organization/quantum-technology-partners). It also has raised venture debt from [Lighthouse Capital Partners](/financial-organization/lighthouse-capital-partners). On April 15th, 2009, French drug maker [Sanofi-Aventis S.A.](/organization/sanofi-aventis-2) announced it was acquiring BiPar Sciences for up to $500 million.
BIPAR SCIENCES
Social Links:
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2002-01-01
Address:
Brisbane, California, United States
Country:
United States
Website Url:
http://www.biparsciences.com
Total Employee:
11+
Status:
Active
Contact:
650-635-6050
Total Funding:
74.97 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Mobile Non Scaleable Content Nginx Baidu Analytics DNS.COM
Current Employees Featured
Founder
Investors List
Vulcan Capital
Vulcan Capital investment in Series C - BiPar Sciences
Canaan Partners
Canaan Partners investment in Series C - BiPar Sciences
PolyTechnos Venture Partners
PolyTechnos Venture Partners investment in Series C - BiPar Sciences
Asset Management Company
Asset Management Company investment in Series C - BiPar Sciences
Asset Management Ventures (AMV)
Asset Management Ventures (AMV) investment in Series C - BiPar Sciences
Domain Associates
Domain Associates investment in Series C - BiPar Sciences
Quantum Technology Partners
Quantum Technology Partners investment in Series C - BiPar Sciences
Sand Hill Angels
Sand Hill Angels investment in Series B - BiPar Sciences
Asset Management Company
Asset Management Company investment in Series B - BiPar Sciences
Sand Hill Angels
Sand Hill Angels investment in Series A - BiPar Sciences
Official Site Inspections
http://www.biparsciences.com
- Host name: 104.247.82.50
- IP address: 104.247.82.50
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "BiPar Sciences"
BiPar Sciences โฃ Empowering Lives through Innovation and โฆ
The European Approach to Holistic Healthcare: Integrating Traditional and Modern Practices - April 23, 2023. In todayโs increasingly interconnected world, the pursuit of holistic healthcare โฆSee details»
BiPar Sciences - Crunchbase Company Profile & Funding
BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar's key experimental product is BSI-201, currently in mid-stage trials for advanced breast โฆSee details»
BiPar Sciences - PitchBook
Information on acquisition, funding, cap tables, investors, and executives for BiPar Sciences. Use the PitchBook Platform to explore the full profile.See details»
BIPAR SCIENCES, INC. - Dun & Bradstreet
Bipar Sciences, Inc. was founded in 2009, and is located at 400 Oyster Point Blvd in South San Francisco. It employs 20 employees and is generating approximately $1,800,000.00 in annual โฆSee details»
New Executive Leadership and CEO Announced for BiPar Sciences
BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. ... For more โฆSee details»
BiPar Sciences, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Jul 12, 2023 Explore BiPar Sciences, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, and 2 literature, Drug:BSI-401, BSI-301.See details»
BiPar Sciences, Inc. - Brisbane, USA - bionity.com
Jul 20, 2009 biparsciences.com +1650635-6050. Share. Xing Linkedin Facebook X E-mail Loading... Bookmark. Bookmark list; Bookmark. BiPar Sciences, Inc. 1000 Marina Blvd., Suite โฆSee details»
BiPar Sciences - Overview, News & Similar companies - ZoomInfo
BiPar Sciences Inc. (www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-sel ective drugs designed to meet the โฆSee details»
BiPar Sciences Inc., Hoyoung Huh, - walkersresearch.com
Www.biparsciences.com Fax: 1-650-635-6057: Summary ; Executive Details ; Board Members ; Business Information The groupโs principle activity is to provide drug development services โฆSee details»
Sanofi-Aventis To Acquire BiPar Sciences
Apr 16, 2009 For more information, please visit www.biparsciences.com. About sanofi-aventis Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes โฆSee details»
BiPar Sciences - Company Information, Competitors, News & FAQs
Find useful insights on BiPar Sciences's company details, tech stack, news alerts, competitors and more. Use 6sense to connect with top decision-makers at BiPar Sciences.See details»
BiPar Sciences - VentureRadar
Similar Companies: Addex Pharmaceuticals SA Switzerland Publicly Traded Addex Pharmaceuticals (Geneva, Switzerland) discovers and develops allosteric modulators for โฆSee details»
New Executive Leadership and CEO Announced for BiPar
Dec 11, 2009 BiPar Sciences is a biopharmaceutical organization dedicated to pioneering novel tumor-selective therapies designed to address urgent unmet needs of cancer patients. ... For โฆSee details»
New Executive Leadership and CEO Announced for BiPar Sciences
Dec 16, 2009 BiPar Chief Executive Officer and President Hoyoung Huh, M.D., Ph.D. will take on a broader role in the sanofi-aventis organization as Chairman of the Board of Directors of โฆSee details»
BiPar Sciences - Products, Competitors, Financials, Employees ...
BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, โฆSee details»
BiPar Sciences, Inc. - discovery.patsnap.com
Discovery Company profile page for BiPar Sciences, Inc. including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
BiPar Sciences - VentureRadar
BiPar Sciences, Inc. develops small molecules for the inhibition of PARP pathways. Indications which have been explored include triple negative... ... Find out more ...See details»
Bipar Sciences - Golden
A pharmacological company that develops PARP inhibitors as cancer therapiesSee details»
BiPar Sciences: Revenue, Competitors, Alternatives
BiPar Sciences is advancing the field of cancer therapy through the development of a novel class of tumor-selective drugs, called PARP inhibitors, designed to target multiple cancer types, โฆSee details»
BiPar Sciences-ๅจ่็ฝ - vbdata.cn
BiPar Sciences, Inc.ๆฏไธๅฎถ็งๆ็็็ฉๅถ่ฏๅ ฌๅธ๏ผๅผๅไบๆฐๅ่ฟ็ค้ๆฉๆง็ๆณ๏ผๆจๅจ่งฃๅณ็็ๆฃ่ ๆชๅพๅฐๆปก่ถณ็่ฟซๅ้ๆฑใ้คBSI-201ๅค๏ผ่ฏฅๅ ฌๅธ่ฟๆไธคไธชๅคไบไธดๅบๅๅผๅ้ถๆฎต็ๅๅ็ฉ๏ผBSI โฆSee details»